Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

United Therapeutic (UTHR) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart


See More
  • Market Capitalization, $K 6,371,580
  • Shares Outstanding, K 43,470
  • Annual Sales, $ 1,466 M
  • Annual Income, $ 652 M
  • 36-Month Beta 1.39
  • Price/Sales 4.00
  • Price/Book 3.55

Price Performance

See More
Period Period Low Period High Performance
138.67 +7.62%
on 12/22/16
153.07 -2.51%
on 01/11/17
+4.69 (+3.24%)
since 12/16/16
110.90 +34.56%
on 10/21/16
153.07 -2.51%
on 01/11/17
+32.26 (+27.58%)
since 10/18/16
97.52 +53.03%
on 06/27/16
153.07 -2.51%
on 01/11/17
+16.13 (+12.12%)
since 01/15/16

Most Recent Stories

More News
VIVUS Licenses Rights to PAH Drugs from Selten Pharma

VIVUS, Inc. (VVUS) acquired exclusive global rights to develop and commercialize pulmonary arterial hypertension (PAH) drugs, tacrolimus and ascomycin from private biotech company, Selten Pharma, Inc.

Dova Pharmaceuticals Announces Hiring of CEO and Presentation at the 35th Annual J.P. Morgan Healthcare Conference

Dova Pharmaceuticals, Inc., a clinical, late-stage company, having recently completed enrollment in two global, pivotal Phase 3 trials, is pleased to announce the appointment of its new CEO,...

New Strong Buy Stocks for January 5th

New Strong Buy Stocks for January 5th

United Therapeutics Corporation To Present At 35th Annual J.P. Morgan Healthcare Conference

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's...

United Therapeutics' PAH Suite Bodes Well, Competition Rife

On Dec 29, 2016, we issued an updated report on United Therapeutics Corporation (UTHR).

Research Reports Coverage on Drug Makers Stocks -- Depomed, DURECT, United Therapeutics, and Amphastar Pharma

The Drug Manufacturers industry is focused on the research, distribution, and marketing of pharmaceutical drug products. Companies in this space typically have dividend yields that are higher than the...

J&J (JNJ) Reportedly Approaches Actelion for Acquisition

Reportedly, Johnson & Johnson (JNJ) recently approached Swiss biotechnology company, Actelion Ltd. (ALIOF), with a potential takeover offer.

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United Therapeutics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, NY / ACCESSWIRE / November 1, 2016 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of United Therapeutics Corporation -- UTHR

NEW YORK, NY / ACCESSWIRE / October 31, 2016 / Levi & Korsinsky announces it has commenced an investigation of United Therapeutics Corporation (NASDAQ: UTHR) concerning possible breaches of fiduciary duty...

United Therapeutics Rises 2.22% on Heavy Volume: Watch For Potential Pullback

United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $118.00 to a high of $121.46. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. These products include pharmaceuticals, arginine products and telemedicine services.

See More

Support & Resistance

2nd Resistance Point 150.80
1st Resistance Point 149.37
Last Price 149.91
1st Support Level 146.94
2nd Support Level 145.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.